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Abstract 
Overweight and obesity are frequently reported to be a significant issue in schizophrenia resulting in the 
inherent complications of these disorders. Body weight gain also commonly results from treatment with 
the most tolerable and efficacious pharmacological treatments, second-generation antipsychotics. 
However there are numerous other factors that contribute to increased body mass in individuals with 
schizophrenia prior to the initiation of treatment. With prior research indicating that individuals with 
schizophrenia have higher rates of overweight and obesity before treatment. Therefore this article 
provides a review of pertinent issues associated with body weight gain in schizophrenia in an attempt to 
delineate the impact of both the disease and treatment upon body weight gain. The results of the review 
indicate that body weight gain in schizophrenia occurs from both psychosocial and biological factors that 
are further compounded by antipsychotic treatment. The article concludes with recommendations for 
future research. 
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Abstract: Overweight and obesity are frequently reported to be 
a  significant  issue  in  schizophrenia  resulting  in  the  inherent 
complications of these disorders. Body weight gain also com-
monly results from treatment with the most tolerable and effica-
cious  pharmacological  treatments,  second-generation  anti-
psychotics. However there are numerous other factors that con-
tribute  to  increased  body  mass  in  individuals  with  schizo-
phrenia prior to the initiation of treatment. With prior research 
indicating that individuals with schizophrenia have higher rates 
of overweight and obesity before treatment. Therefore this art-
icle provides a review of pertinent issues associated with body 
weight gain in schizophrenia in an attempt to delineate the im-
pact of both the disease and treatment upon body weight gain. 
The  results  of  the  review indicate  that  body  weight  gain  in 
schizophrenia  occurs  from  both  psychosocial  and  biological 
factors that are further compounded by antipsychotic treatment. 
The  article  concludes  with  recommendations  for  future  re-
search. 
Key Words: Body weight gain; Psychosocial factors; Biologic-
al factors; Schizophrenia; Overweight; Obesity 
Introduction:
The  relationship  between  schizophrenia  and  increased  body 
weight  was  identified  prior  to  the  advent  of  the  first  anti-
psychotics to treat the disease.[1] This association was first de-
scribed in the early 1900’s in the writings of Emil Kraepelin on 
the disorder then termed ‘dementia praecox’; the first nomen-
clature of schizophrenia symptomology.[1]
Epidemiologically it is also evident that individuals who suffer 
from schizophrenia have higher rates of overweight and obesity 
in comparison to the general population.[2,3] A study conduc-
ted by Thakore and colleagues [4] found that both drug-naive 
and  drug-free  patients  with  schizophrenia  had  higher  BMI’s 
and waist to hip ratios than age and sex matched controls. 
After  the  introduction  of  the  first  conventional  antipsychotic 
chlorpromazine, in the 1950’s body weight gain (BWG) as a 
side effect of treatment  was reported.[1] However BWG was 
not viewed as one of the most detrimental side effects due to 
conventional  antipsychotics  having  other  serious  side  effects, 
such as extrapyramidal  symptoms,  and inducing significantly 
less BWG than second generation antipsychotics (SGA). 
Although SGA have superior tolerability and efficacy in com-
parison  to  conventional  neuroleptic  treatment  [5]  they  com-
monly induce clinically significant BWG.[6] That is an increase 
in body weight that is ≥7% of the individual’s body weight at 
the initiation of treatment.[6]
Even though the challenge of increased body mass of individu-
als with schizophrenia proportionate to the general population 
has been identified for more than a century; there is relatively 
scarce  literature  on  the  issue  relative  to  the  scope  and  con-
sequences of  the  problem.  In regards to  SGA-induced BWG 
there has been a plethora  of  research. The issue of BWG in 
schizophrenia is complex and multi-faceted resulting not only 
from treatment but also from the disease itself in addition to the 
social and cultural environment. Therefore this article attempts 
to further clarify the means by which BWG occurs in schizo-
phrenia. 
The Genesis of Body Weight Gain & the Consequences
An increase in body mass or BWG generally results from a cal-
oric intake that is higher than the expended energy rate. Energy 
is  expended through  the  basal  metabolic  rate,  thermogenesis 
and physical activity.[3] BWG as a result of SGA treatment is 
thought  to  result  from the  same  genesis  as  BWG  generally. 
Within the general population it has been found that even fid-
geting combined with exercises of daily living excluding phys-
ical activity is enough to provide sedentary individuals with a 
protective barrier against obesity.[7]
An  increase  in  body  weight  can  result  in  overweight  and 
obesity  and  the  inherent  complications  of  these  disorders. 
Namely, metabolic syndromes such as type II diabetes, cardi-
ovascular disease, hypotension and some forms of cancer.[3] In 
addition  to the physical  toll  of  overweight  and obesity  these 
disorders also incur a psychological toll. Reducing self-esteem 
and body image and leading to greater social deprivation than 
what the patient is already experiencing due to schizophrenia 
symptomology.[3]
Innate Nature of Schizophrenia
One of the most obvious causal mechanisms that may predis-
pose individuals with schizophrenia to body weight changes is 
the  innate  nature  of  the  illness.  Specifically  the  cognitive 
impairment  that  results  from psychosis  and  the  motivational 
impact of negative symptomology such as flattened affect may 
induce  poor  lifestyle  choices.[3,8]  That  is  unhealthy  dietary 
choices, substance use / abuse and decreased levels of physical 
activity. These symptoms also promote social isolation leading 
to fewer opportunities for activity and thus reduced energy ex-
penditure.
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Environmental Mechanisms
In recent times there has been a proliferation in the number of 
individuals in the general population suffering from overweight 
and obesity.[3] This increase is thought to have resulted from 
the influence of an obesigenic environment evident in industri-
alised societies. That is an immense increase in access to high 
calorie  convenience  food  coupled  with  reduced opportunities 
for physical activity due to labour saving devices, sedentary oc-
cupations and inactive past times. 
Furthermore social deprivation and exclusion are thought to be 
a causal mechanism that can contribute to the onset of schizo-
phrenia as well as being maintained through the nature of the 
illness [9]. A component of social deprivation is socio-econom-
ic status (SES); which directly affects body weight by mediat-
ing the availability of healthy food choices along with know-
ledge of healthy lifestyle factors. Therefore it is not surprising 
that this increase in overweight and obesity is also apparent in 
individuals suffering from schizophrenia. 
Dietary Preferences
Although there is not a great deal of research on the diets of in-
dividuals with schizophrenia the existing evidence indicates an 
exaggerated predilection for a diet  of  palatable foodstuffs.[2] 
Palatable foods are those that induce cravings for consumption 
(i.e. lollies); and when consumed evoke pleasure and positive 
affective states. As oppose to non-palatable foods such as broc-
coli.  Specifically  individuals  with  schizophrenia  have  prefer-
ence for a diet high in convenience foods that are high in satur-
ated  fat  and  carbohydrates  and  low  in  fibre,  such  as  that 
provided by fruit and vegetables.[3]
Furthermore  there  is  strong correlational  evidence  to  suggest 
that a diet high in sugar and saturated fat produces poorer ill-
ness outcomes in individuals suffering from schizophrenia.[10] 
Whereas the  consumption  of  pulses  resulted in  better  illness 
outcomes;  that is  less  hospitalisations  and less social  impair-
ment.[10] Thus individuals in developing nations consuming a 
non-westernised diet and without access to convenience food-
stuffs fair better than individuals with schizophrenia in industri-
alised countries.[2,10]
Inherent Metabolic Disadvantage
Metabolic  syndrome  is  a  group  of  disorders  consisting  of 
obesity,  glucose  intolerance,  insulin  resistance  and  dyslipid-
aemias that are highly related to the occurrence of type II dia-
betes mellitus  and cardiovascular disease.[4] It  has also been 
suggested that individuals that are suffering from schizophrenia 
have an inherent metabolic disadvantage that predisposes them 
to  the  onset  of  metabolic  syndromes.[2]  Additionally  it  is 
known that individuals with schizophrenia have increased rates 
of metabolic syndromes above that of the general population. 
That is  the  metabolic  disadvantage  does not  just  result  from 
SGA treatment as reports of glucose problems in patients with 
schizophrenia were recorded prior to the advent of neuroleptic 
treatments.[4] Elman, Borsook and Lukas [2] have tentatively 
proposed that obesity in schizophrenia may partly result from 
glucose metabolism issues that are evident in individuals with 
schizophrenia. An inverse relationship to what is currently con-
ceptualised.
For example the higher rates of type II diabetes mellitus maybe 
a function of the disease and not the treatment.[2,4] Empirical 
research has found that first-degree relatives of individuals with 
schizophrenia who do not have schizophrenia themselves have 
higher rates of type II diabetes than the general population [4], 
thus indicating a possible genetic relationship between schizo-
phrenia and type II diabetes. In fact, current evidence suggests 
inherent abnormalities of insulin signalling pathway in schizo-
phrenia.[11]
In addition another factor that is implicated in the aetiology of 
schizophrenia is Insulin–like Growth Factor 1 (IGF-1). IGF-1 is 
so  named  due  to  its  similarity  to  insulin.  According  to  the 
neurodevelopmental model of schizophrenia deficits of IGF-1 
affect prenatal and postnatal development acting as a pathogen-
esis for schizophrenia.[12] A deficit IGF-1 has also been im-
plicated  in  insulin  resistance.[13]  This  is  further  supported 
through recent studies that have found lower levels of IGF-1 in 
drug naive individuals with schizophrenia in comparison to age 
and sex matched controls.[12,13] 
Furthermore it has been demonstrated that obesity has a very 
strong  heritable  component  with  45-85% of  the  variation  in 
BMI is estimated to be accounted for by genetics.[14] This is  
similar  to the aetiological  contribution  of  genetics to  schizo-
phrenia.[8] 
Neurological Reward & Inhibition Mechanisms
Neurological and neuroanatomical abnormalities beyond the ef-
fect of SGA therapy have been implicated in driving the desire 
for sweet and fatty foodstuffs in schizophrenia through reward 
and  inhibition  mechanisms.  Specifically  neuroanatomical  ab-
normalities  have been identified in the reward and reinforce-
ment circuits in patients with schizophrenia through neuroima-
ging, preclinical and clinical studies.[2] In particular, a hyper-
functional  state  of  the  mesolimboic  dopaminergic  system in 
schizophrenia may cause motivational reward system insensit-
ive to palatable food.[2]
This  reward  deficiency  is  further  highlighted  by the  clinical 
symptomology of the illness namely;  anhedonia, flattened af-
fect and avolition as well as being reflected in the high co-mor-
bidity  for  substance  abuse disorders.[2]  The neurological  ab-
normalities coupled with these symptoms induce a reward defi-
cit  that  requires  higher  levels  of  stimulation;  sweeter,  fattier 
foodstuffs in large quantities in order to satisfy the desire or 
craving.
It  is thought that the same reward and inhibition mechanisms 
that drive the desire to seek and consume drugs and alcohol in 
substance use disorders also mediate the desire to seek and con-
sume palatable foodstuff. As it  has been found that palatable 
foods activate the dopaminergic reward system; in addition it is 
also evident that chronic consumption of sweet and fatty foods 
can alter the dopaminergic reward system.[2,15] This alteration 
results  in  the  individual  becoming  susceptible  to  over  eating 
and food addiction; through conditioning processes.  
Furthermore both palatable foods and drugs are known to in-
crease the release of endogenous opiates.[2,15] Although there 
are limited human studies, the chronic consumption of palatable 
food sources can result in neuroadaptations in the opiod recept-
ors resulting in opiod dependence. Further driving the desire to 
seek and consume unhealthy foodstuffs. 
This desire to seek and consume palatable food is further ex-
acerbated  by  the  ability  of  the  individual  to  utilise  control 
mechanisms. Studies with both obese and drug-addicted indi-
viduals  have  indicated  increased  prefrontal  cortex  activation 
and decreased performance on a cognitive task in response to 
food  stimuli  and drug stimuli,  respectively.[2,14]  This  hypo-
functionality of the prefrontal cortex results in inhibitory con-
trol thus leading to over eating or the consumption of drugs. In 
addition recently Volkow and colleagues [15] have found that 
addiction not only impacts upon the dopaminergic reward cir-
cuits  but  is  also  involved  in  conditioning  or  the  forming  of 
habits, motivation as well as executive functioning.
SGA Induced BWG
With regards to antipsychotic-induced BWG in schizophrenia, 
the  neurological  mechanisms  through  which  SGA  treatment 
results in weight gain are yet to be fully elucidated.[16] It  is  
thought that SGA-induced BWG results primarily from an in-
crease in appetite.[3,16] However it is also postulated that a de-
crease in energy expenditure may also contribute to SGA-in-
duced BWG.[3]
That is SGA’s are known to induce appetite in individuals with 
schizophrenia; specifically an appetite for unhealthy foodstuffs.
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[3] This cumulatively impacts upon their already existing pre-
dilection  for  palatable  foodstuffs  and  their  predisposition  to 
metabolic  syndromes.  This  further  induces  neurological  and 
neuroanatomical  changes  in  individuals  with  schizophrenia 
which may result in food addiction.
In regards to reduced energy expenditure a common side effect 
of SGA treatment is sedation. This sedation may result in a lack 
of  participation  in  physical  activity  further  contributing  to 
weight gain.[3]
Discussion:
From the above review it is apparent that there are numerous 
factors beyond treatment with SGA that induce BWG in some 
individuals  with  schizophrenia.  There  is  substantial  evidence 
that individuals’ with schizophrenia are already predisposed to 
making poor food choices through the social and cultural envir-
onment and the symptomology of the disease.
Figure 1: The Cumulative Process of BWG in
Schizophrenia
This figure depicts the multiple factors that can result in BWG 
in schizophrenia, each of these factors either emanates from or 
interacts with the innate nature of schizophrenia resulting in a 
cumulative process of BWG
This is further exacerbated by neuroanatomical  abnormalities 
evident in some individuals in schizophrenia that result in a re-
ward  deficient  and  a  lack  of  executive  functioning.  Thus 
through this deficit and conditioning processes individuals be-
come vulnerable to food addiction. This further strengthens the 
predilection for palatable foodstuffs. The effect of a diet of sug-
ary and fatty foodstuffs is further compounded by the inherent 
metabolic disadvantage in some individuals with schizophrenia. 
These  pre-existing  factors  are  further  compounded  by  SGA 
treatment resulting in greater amounts of BWG. The compon-
ents of this cumulative process of weight gain are illustrated in 
figure 1 above.
Although there is strong empirical and theoretical evidence that 
each of these factors can contribute to BWG for some individu-
als with schizophrenia. It remains less clear as to which indi-
viduals  are  predisposed  to  BWG  through  each of  the  above 
factors.  In  addition  the  hypothesized  cumulative  nature  of 
BWG in schizophrenia needs to be tested. 
Furthermore future research should also investigate the diets of 
individuals with schizophrenia specifically; trying to ascertain 
individual and illness differences between individuals with poor 
and ‘good’ food choices. Such endeavours could both highlight 
those that are at an increased risk of BWG as well as inform 
lifestyle interventions. 
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